Skip to main content

Advertisement

SpringerLink
Log in

RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

An Erratum to this article was published on 30 May 2006

Abstract

Purpose: Aldehyde dehydrogenases class-1A1 (ALDH1A1) and class-3A1 (ALDH3A1) have been associated with resistance to cyclophosphamide (CP) and its derivatives. We have previously reported the downregulation of these enzymes by all-trans retinoic acid (ATRA). Methods: In this study, we used siRNA duplexes as well as retrovirally expressed siRNA to knockdown one or both enzymes together in A549 lung cancer cell line in order to investigate the role of each one in mediating the resistance and the effect of the addition of ATRA. Results: The results show that significant and specific knockdown of each enzyme can be achieved and that each one contributes similarly to cell resistance to 4-hydroperoxycyclophosphamide (4-HC), an active derivative of CP. Added effects were seen when both enzymes were inhibited. The addition of ATRA also exhibited additional inhibitory effects on ALDH activity and increased 4-HC toxicity when added to single siRNA aimed at one of the enzymes. On the other hand, ATRA had minimal and insignificant additional inhibitory effects on ALDH enzyme activity when added to a combination of siRNAs against both enzymes, but still increased 4-HC toxicity beyond that seen with RNAi-mediated inhibition of both enzymes together. Conclusions: We conclude that both enzymes, ALDH1A1 and ALDH3A1 will need to be blocked in order to achieve the highest sensitivity to 4-HC. Furthermore, ATRA increases 4-HC toxicity even when added to a combination of siRNAs against both enzymes, thus suggesting additional mechanisms by which ATRA can increase drug toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Vasiliou V, Pappa A, Peterson DR (2000) Role of aldehyde dehydrogenase in endogenous and xenobiotic metabolism. Chem Biol Interact 129:1–19

    Article  PubMed  CAS  Google Scholar 

  2. Sophos NA, Pappa A, Ziegler TL, Vasiliou V (2001) Aldehyde dehydrogenase gene superfamily: the 200 update. Chem Biol Interact 130–132:323–337

    Article  PubMed  Google Scholar 

  3. Sladek NE (2003) Human aldehyde dehydrogenase: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol 17:7–23

    Article  PubMed  CAS  Google Scholar 

  4. Hilton J (1984) Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 44:5156–5160

    PubMed  CAS  Google Scholar 

  5. Manthey CL, Landkamer GJ, Sladek NE (1990) Identification of the mouse aldehyde dehydrogenases important in aldophosphamide detoxification. Cancer Res 50:4991–5002

    PubMed  CAS  Google Scholar 

  6. Sreerama L, Sladek NE (1993) Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem Pharmacol 45:2487–2505

    Article  PubMed  CAS  Google Scholar 

  7. von Eitzen U, Meier-Tackmann D, Agarwal DP, Goedde HW (1994) Detoxification of cyclophosphamide by human aldehyde dehydrogenase isozymes. Cancer Lett 76:45–49

    Article  PubMed  Google Scholar 

  8. Yoshida A, Rzhetsky A, Hsu LC, Chang C (1998) Human aldehyde dehydrogenase gene family. Eur J Biochem 251:549–557

    Article  PubMed  CAS  Google Scholar 

  9. Bunting KD, Lindahl R, Townsend AJ (1994) Oxazaphosphorine-specific resistance in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase. J Biol Chem 269:23197–23203

    PubMed  CAS  Google Scholar 

  10. Bunting KD, Townsend AJ (1996) De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anti-cancer alkylating agents in hamster V79 cell lines. Elevated class 1 ALDH activity is closely correlated with reduction in DNA interstrand cross-linking and lethality. J Biol Chem 271:11884–11890

    Article  PubMed  CAS  Google Scholar 

  11. Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, Gianni AM (1996) Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 87:1097–1103

    PubMed  CAS  Google Scholar 

  12. Moreb J, Schweder M, Suresh A, Zucali JR (1996) Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Ther 3:24–30

    PubMed  CAS  Google Scholar 

  13. Moreb JS, Schweder M, Gray B, Zucali J, Zori R (1998) In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4-hydroperoxycyclophosphamide. Hum Gene Ther 9:611–619

    PubMed  CAS  Google Scholar 

  14. Moreb JS, Maccow C, Schweder M, Hecomovich J (2000) Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. J Pharmacol Exp Ther 293:390–396

    PubMed  CAS  Google Scholar 

  15. Moreb JS, Gabr A, Vartikar GR, Gowda S, Zucali JR, Mohuczy D (2005) Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. J Pharmacol Exp Ther 312:339–345

    Article  PubMed  CAS  Google Scholar 

  16. Zamore PD (2001) RNA interference: listening to the sound of silence. Nat Struct Biol 8:746–750

    Article  PubMed  CAS  Google Scholar 

  17. Bernstein E, Denli AM, Hannon GJ (2001) The rest is silence. RNA 7:1509–1521

    PubMed  CAS  Google Scholar 

  18. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498

    Article  PubMed  CAS  Google Scholar 

  19. Tuschl T (2002) Expanding small RNA interference. Nat Biotech 20:446–448

    Article  PubMed  CAS  Google Scholar 

  20. Paul CP, Good PD, Winer I, Engelke DR (2002) Effective expression of small interfering RNA in human cells. Nat Biotech 20:505–508

    Article  PubMed  CAS  Google Scholar 

  21. Tuschl T, Borkhardt A (2002) Small interference RNAs: a revolutionary tool for the analysis of gene function and gene therapy. Mol Interv 2:158–167

    Article  PubMed  CAS  Google Scholar 

  22. Sladek NE, Kollander R, Sreerama L, Kiang DT (2002) Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 49:309–321

    Article  PubMed  CAS  Google Scholar 

  23. Szeto W, Jiang W, Tice DA, Rubinfeld B, Hollingshead PG, Fong SE, Dugger DL, Pham T, Yansura DG, Wong TA, Grimaldi JC, Corpuz RT, Singh JS, Frantz GD, Devaux B, Crowley CW, Schwall RH, Eberhard DA, Tastelli L, Polakis P, Pennica D (2001) Overexpression of the retinoic aci-responsive gene stra6 in human cancers and its synergistic induction by Wnt-1 and retinoic acid. Cancer Res 61:4197–4205

    PubMed  CAS  Google Scholar 

  24. Sreerama L, Norman SE (2001) Three different stable human breast adenocarcinoma sublines that overexpress ALDH3A1 and certain other enzymes, apparently as a consequence of constitutively upregulated gene transcription mediated by transactivated EpREs (electrophile responsive elements) present in the 5′-upstream regions of these genes. Chem Biol Interact 130–132:247–260

    Article  PubMed  Google Scholar 

  25. Sreerama L, Sladek NE (1996) Class I and class 3 aldehyde dehydrogenase levels in the human tumor cell lines currently used by the National Cancer Institute to screen for potentially useful antitumor agents. Adv Exp Med Biol 414:81–94

    Google Scholar 

  26. Choudhary S, Xiao T, Vergara LA, Srivastava S, Nees D, Piatigorsky J, Anusari NH (2005) Role of aldehyde dehydrogenase isozymes in the defense of rat lens and human lens epithelial cells against oxidative stress. Invest Ophthalmol Vis Sci 46:259–267

    Article  PubMed  Google Scholar 

  27. Haselbeck RJ, Hoffman I, Duester G (1999) Distinct functions for Aldh1 and Raldh2 in the control of ligand production for embryonic retinoid signaling pathways. Dev Genet 25:353–364

    Article  PubMed  CAS  Google Scholar 

  28. Pappa A, Brown D, Koutalos Y, DeGregori J, White C, Vasiliou V (2005) Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells. J Biol Chem 280: 27998–28006

    Article  PubMed  CAS  Google Scholar 

  29. Formelli F, Cleris L (1993) Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 53:5374–5376

    PubMed  CAS  Google Scholar 

  30. Shalinsky DR, Bischoff ED, Gregory ML, Lamph WW, Heyman RA, Hayes JS, Thomazy V, Davies PJ (1996) Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice. Clin Cancer Res 2:511–520

    PubMed  CAS  Google Scholar 

  31. Grunt T, Dittrich E, Offterdinger M, Schneider SM, Dittrich C, Huber H (1998) Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Br J Cancer 78:79–87

    PubMed  CAS  Google Scholar 

  32. Kalemkerian GP, Ou X (1999) Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines. Cancer Chemother Pharmacol 43:145–150

    Article  PubMed  CAS  Google Scholar 

  33. Pettersson F, Colston KW, Dalgleish AG (2001) Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas 23:273–279

    Article  PubMed  CAS  Google Scholar 

  34. Shankar P, Manjunath N, Lieberman J (2005) The prospect of silencing disease using RNA interference. JAMA 293:1367–1373

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology/Oncology, University of Florida, College of Medicine, 1600 SW Archer Road, Room R4-220, PO Box 100277, Gainesville, FL, 32610, USA

    Jan S. Moreb, Dagmara Muhoczy, Blanca Ostmark & James R. Zucali

Authors
  1. Jan S. Moreb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dagmara Muhoczy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Blanca Ostmark
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James R. Zucali
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan S. Moreb.

Additional information

Financial support for this work was provided by a grant (to JSM) from the Flight Attendant Medical Research Institute (Miami, FL).

An erratum to this article can be found at http://dx.doi.org/10.1007/s00280-006-0268-8

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moreb, J.S., Muhoczy, D., Ostmark, B. et al. RNAi-mediated knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is specific and reveals that each contributes equally to the resistance against 4-hydroperoxycyclophosphamide. Cancer Chemother Pharmacol 59, 127–136 (2007). https://doi.org/10.1007/s00280-006-0233-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0233-6

Keywords

Search

Navigation